AMPK–SQSTM1 Feedback in Metabolic Stress

Metabolic stress requires cells to balance energy conservation with protection against oxidative damage. The study by Choi and colleagues describes a feedback circuit that links these responses: AMPK supports the induction and phosphorylation of SQSTM1/p62, while p62 helps reactivate AMPK and also promotes NFE2L2/NRF2 signaling. This reciprocal relationship connects lysosomal changes to antioxidant defense and offers a mechanistic perspective on tumor adaptation under nutrient limitation.

The central contribution is not simply that AMPK and NRF2 can both respond to stress. Rather, the authors propose that SQSTM1/p62 helps coordinate their activation through distinct molecular routes, while AMPK activity feeds back to sustain p62. The resulting model is relevant to cancer biology, but its implications should be interpreted within the limits of the experimental systems and pathways examined.

Study Background and Research Question

In a nutrient-poor tumor microenvironment, reduced glucose availability can constrain energy production and diminish the supply of metabolites needed to maintain NADPH and redox balance. Reactive oxygen species (ROS) can further impair mitochondrial function, adding oxidative stress to the original metabolic challenge. AMPK, activated during energy stress, helps cells adjust energy use and support processes that preserve metabolic balance.

A separate stress-response route centers on KEAP1 and NFE2L2/NRF2. KEAP1 normally limits NRF2 activity; when KEAP1 is degraded, NRF2 can drive antioxidant-response programs. The paper focuses on how this route interacts with STK11/LKB1–AMPK signaling, particularly in the context of co-occurring STK11 and KEAP1 alterations reported in non-small cell lung cancer. The authors ask how metabolic stress changes SQSTM1/p62 and whether p62 links lysosomal signaling to both AMPK and NRF2 activation. The reference study frames this question as a way to understand coordinated adaptation, not as proof that one pathway alteration alone determines tumor behavior.

Key Innovation from the Reference Study

The study’s key innovation is its double-positive feedback model. Under metabolic stress, AMPK activity contributes to increased SQSTM1 expression and phosphorylation. In turn, SQSTM1 promotes AMPK activation and stimulates NRF2 through two related but distinguishable mechanisms. It supports formation of an AXIN–STK11–AMPK complex at the lysosomal membrane, and it promotes autophagic degradation of KEAP1, relieving suppression of NRF2.

This model gives p62 a coordinating role rather than treating it only as an autophagy-associated cargo adaptor or a downstream stress marker. It also links the two signaling outputs to lysosomal state: lysosomal processes help organize AMPK activation, while KEAP1 degradation provides a route to NRF2 activation. The reported importance of phosphorylation at SQSTM1 S24 and S226 further suggests that p62 regulation involves specific modification sites, not merely a general increase in p62 abundance. These mechanisms and site-specific findings are described in the paper’s results.

Methods and Experimental Design Insights

The experimental logic is useful for researchers studying stress-response crosstalk. The authors examined changes in SQSTM1 expression and phosphorylation alongside AMPK and NRF2 pathway activity, then connected these readouts to lysosomal function, KEAP1 turnover, and formation of the AXIN–STK11–AMPK complex. The interpretation rests on testing relationships among these events, rather than treating a single marker such as total p62 or NRF2 abundance as sufficient evidence for pathway activation.

The study also distinguishes upstream conditions that contribute to p62 regulation. Low-glucose metabolism and AMPK-dependent proton reduction were associated with lysosomal deacidification and PPP2/PP2A-dependent dephosphorylation of TFEB and TFE3, factors linked to increased SQSTM1 expression. In parallel, ROS and pH-dependent lysosomal calcium release were associated with MAP3K7/TAK1 activation and increased p62 phosphorylation. These are separate parts of the proposed regulatory chain; measuring only one branch could miss how metabolic and oxidative inputs converge.

For experimental planning, the paper therefore supports a panel-based approach: pair metabolic-stress conditions with measurements of p62 abundance and phosphorylation, AMPK activity, NRF2 pathway output, and relevant lysosomal or KEAP1 readouts. Include controls that distinguish changes in lysosomal pH from general nutrient stress, and consider whether the chosen cell model retains the pathway components being tested. The results report that lactic-acid-derived protons abrogated stress-associated effects, making extracellular pH and proton availability important variables to control. The article does not establish a universal dose or exposure time for every cell model, so those settings should be optimized rather than transferred uncritically.

Protocol Parameters

• Stress condition: The study links low-glucose metabolic stress with lysosomal deacidification and SQSTM1 regulation. As a workflow recommendation, compare a defined low-nutrient condition with a matched nutrient-replete control; establish duration and intensity in the cell type being used.
• pH and proton control: The paper reports that protons provided by lactic acid abrogated the effects attributed to metabolic stress. As a workflow recommendation, monitor and control medium pH when comparing conditions, and avoid interpreting lactate exposure as a pathway-specific manipulation without appropriate controls.
• Pathway readouts: The reported model connects p62 expression and phosphorylation with AMPK, KEAP1 turnover, NRF2, and lysosomal signaling. As a workflow recommendation, measure complementary readouts rather than relying on total p62 or a single antioxidant marker.
• Phosphorylation sites: SQSTM1 S24 and S226 were reported as important for AMPK and NRF2 activation. This is a study finding, not a universal assay specification; use site-aware approaches where available and verify antibody or construct specificity in the chosen system.

Core Findings and Why They Matter

First, metabolic stress increased both SQSTM1 expression and phosphorylation. The authors connect increased expression to lysosomal deacidification, PP2A activity, and regulation of TFEB and TFE3. They connect phosphorylation to ROS and pH-sensitive lysosomal calcium signaling through MAP3K7/TAK1. Together, these findings suggest that p62 responds to more than one feature of a stressed cellular environment.

Second, SQSTM1 was required for the study’s reported dual activation of AMPK and NRF2. On the AMPK side, p62 facilitated assembly of the AXIN–STK11–AMPK complex at lysosomes. On the NRF2 side, p62 promoted autophagic KEAP1 degradation. The distinction matters experimentally: AMPK activation and NRF2 activation are coordinated in the model, but they are not interchangeable readouts and should be assessed separately.

Third, the relationship was reciprocal. STK11–AMPK activity was also required for stress-induced increases in SQSTM1 expression and phosphorylation, creating the proposed double-positive feedback loop. Phosphorylation at S24 and S226 was particularly important for the dual response. By connecting lysosomal state, energy sensing, autophagy, and antioxidant signaling, this feedback model helps explain how tumor cells may maintain stress tolerance. It also offers a mechanistic context for considering co-occurring STK11 and KEAP1 pathway alterations, without establishing that the feedback loop is the sole explanation for their occurrence or consequences.

Comparison with Existing Internal Articles

The internal article AMPK–SQSTM1 Feedback Under Metabolic Stress summarizes the same general feedback concept and its connection to lysosomal signaling, KEAP1 degradation, and NRF2. It is a useful companion overview, but it is not an independent replication of the reference study. The present discussion emphasizes the proposed upstream routes to p62 expression and phosphorylation and the need to distinguish the AMPK and NRF2 outputs when designing experiments.

Limitations and Transferability

The findings establish a mechanistic model in the experimental contexts studied; they do not by themselves show that the same sequence operates in every tumor type, patient-derived model, or tissue under nutrient stress. The relationship between pathway status and tumor growth may depend on cellular background, the severity and duration of stress, and the availability of STK11, KEAP1, and lysosomal signaling components. Likewise, the reported importance of particular p62 phosphorylation sites should be tested in the relevant model rather than assumed to generalize without qualification.

There is also a distinction between pathway activation and therapeutic outcome. The study provides a rationale for investigating how AMPK–SQSTM1 and KEAP1–NRF2 signaling support adaptation, but it does not establish that inhibiting any one component will have a uniform anticancer effect. Follow-up work should preserve the paper’s central separation of mechanistic questions: which changes arise from lysosomal pH, which require AMPK, and which depend on p62-mediated KEAP1 turnover?

Why this cross-domain matters, maturity, and limitations

TRPV1 signaling is a different research domain from the AMPK–SQSTM1 pathway studied here. The reference paper does not test TRPV1, sensory neurons, capsaicin responses, or pain mechanisms, so its findings should not be presented as evidence for a direct connection between TRPV1 and the metabolic-stress feedback loop. The practical relationship is methodological: researchers may study both metabolic adaptation and sensory signaling in separate experimental programs, while keeping their biological claims distinct. The internal overview AMG 9810: TRPV1 Antagonism Under Stress discusses that boundary in the context of sensory-neuron assay design. This is a workflow-level bridge only; it does not increase the maturity of evidence for a shared mechanism.

Research Support Resources

For separate sensory neuron signaling studies, researchers can use AMG 9810 (SKU B7018), a TRPV1 antagonist described for studying capsaicin-evoked channel responses. Product information reports inhibition of capsaicin-induced calcium influx and CGRP release in cultured rat dorsal root ganglion neurons, making it relevant to a CGRP release inhibition assay or pain mechanism research. These applications are distinct from the AMPK–SQSTM1 experiments discussed above; AMG 9810 is not a probe of that feedback loop.